240 related articles for article (PubMed ID: 28100259)
1. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
[TBL] [Abstract][Full Text] [Related]
2. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.
Cimino-Reale G; Gandellini P; Santambrogio F; Recagni M; Zaffaroni N; Folini M
J Hematol Oncol; 2017 Jul; 10(1):140. PubMed ID: 28716051
[TBL] [Abstract][Full Text] [Related]
3. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.
Mackiewicz M; Huppi K; Pitt JJ; Dorsey TH; Ambs S; Caplen NJ
Breast Cancer Res Treat; 2011 Nov; 130(2):663-79. PubMed ID: 21814748
[TBL] [Abstract][Full Text] [Related]
4. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
Belfiore A; Busico A; Bozzi F; Brich S; Dallera E; Conca E; Capone I; Gloghini A; Volpi CC; Cabras AD; Pilotti S; Baratti D; Guaglio M; Deraco M; Kusamura S; Perrone F
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752449
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-34a inhibits cell invasion and epithelial-mesenchymal transition via targeting AXL/PI3K/AKT/Snail signaling in nasopharyngeal carcinoma.
Jiang C; Cheng Z; Jiang T; Xu Y; Wang B
Genes Genomics; 2020 Aug; 42(8):971-978. PubMed ID: 32648233
[TBL] [Abstract][Full Text] [Related]
6. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
[TBL] [Abstract][Full Text] [Related]
7. miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma.
El Bezawy R; Percio S; Ciniselli CM; De Cesare M; Colella G; Dugo M; Veneroni S; Doldi V; Martini S; Baratti D; Kusamura S; Verderio P; Deraco M; Gandellini P; Zaffaroni N; Zuco V
Cancer Gene Ther; 2022 Oct; 29(10):1394-1404. PubMed ID: 35352023
[TBL] [Abstract][Full Text] [Related]
8. An integrated approach of bioinformatic prediction and in vitro analysis identified that miR-34a targets
Hajalirezay Yazdi S; Paryan M; Mohammadi-Yeganeh S
Cell Mol Biol Lett; 2018; 23():51. PubMed ID: 30386383
[TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
10. Cancer-associated fibroblasts contribute to oral cancer cells proliferation and metastasis via exosome-mediated paracrine miR-34a-5p.
Li YY; Tao YW; Gao S; Li P; Zheng JM; Zhang SE; Liang J; Zhang Y
EBioMedicine; 2018 Oct; 36():209-220. PubMed ID: 30243489
[TBL] [Abstract][Full Text] [Related]
11. Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
Ou WB; Hubert C; Corson JM; Bueno R; Flynn DL; Sugarbaker DJ; Fletcher JA
Neoplasia; 2011 Jan; 13(1):12-22. PubMed ID: 21245936
[TBL] [Abstract][Full Text] [Related]
12. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.
De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N
J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896
[TBL] [Abstract][Full Text] [Related]
13. LncRNA XIST/miR-34a axis modulates the cell proliferation and tumor growth of thyroid cancer through MET-PI3K-AKT signaling.
Liu H; Deng H; Zhao Y; Li C; Liang Y
J Exp Clin Cancer Res; 2018 Nov; 37(1):279. PubMed ID: 30463570
[TBL] [Abstract][Full Text] [Related]
14. MiR-34a suppresses ovarian cancer proliferation and motility by targeting AXL.
Li R; Shi X; Ling F; Wang C; Liu J; Wang W; Li M
Tumour Biol; 2015 Sep; 36(9):7277-83. PubMed ID: 25895459
[TBL] [Abstract][Full Text] [Related]
15. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
16. AXL regulates mesothelioma proliferation and invasiveness.
Ou WB; Corson JM; Flynn DL; Lu WP; Wise SC; Bueno R; Sugarbaker DJ; Fletcher JA
Oncogene; 2011 Apr; 30(14):1643-52. PubMed ID: 21132014
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer.
Mudduluru G; Ceppi P; Kumarswamy R; Scagliotti GV; Papotti M; Allgayer H
Oncogene; 2011 Jun; 30(25):2888-99. PubMed ID: 21317930
[TBL] [Abstract][Full Text] [Related]
18. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
19. Assessment of
Pishkari S; Hadavi R; Koochaki A; Razaviyan J; Paryan M; Hashemi M; Mohammadi-Yeganeh S
Horm Mol Biol Clin Investig; 2021 Mar; 42(3):265-271. PubMed ID: 33769725
[TBL] [Abstract][Full Text] [Related]
20. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway.
Ma Y; Qin H; Cui Y
Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
